deltatrials
Completed PHASE3 NCT01393613

Efficacy Study of OPC-34712 in Adults With Acute Schizophrenia

A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Fixed-dose OPC-34712 in the Treatment of Adults With Acute Schizophrenia

Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.

Conditions Acute Schizophrenia
Interventions OPC-34712 Placebo
Updated 7 times since 2017 Last updated: Oct 26, 2015 Started: Jul 31, 2011 Primary completion: Feb 28, 2014 Completion: Feb 28, 2014

Listed as NCT01393613, this PHASE3 trial focuses on Acute Schizophrenia and remains completed. Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc., it has been updated 7 times since 2011, reflecting limited change activity. Mental health research at this phase helps define safety and dosing parameters for future study.

Change History

7 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  4. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE3

  5. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE3

▶ Show 2 earlier versions

  1. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE3

  2. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE3

    First recorded

Jul 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Otsuka Pharmaceutical Development & Commercialization, Inc.
Data source: Otsuka Pharmaceutical Development & Commercialization, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Arkhangelsk, Russia, Austin, United States, Bogotá, Colombia, Bojnice, Slovakia, Bratislava, Slovakia, Buffalo, United States, Cebu City, Philippines, Col. Florida, Mexico, Dallas, United States, Davano City, Philippines and 42 more location s